These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19826362)

  • 1. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Validation of surrogate endpoints in digestive oncology].
    Methy N; Bedenne L; Bonnetain F
    Bull Cancer; 2009 May; 96(5):591-5. PubMed ID: 19423485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments.
    Piedbois P; Buyse M
    Curr Opin Oncol; 2008 Jul; 20(4):466-71. PubMed ID: 18525345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing surrogates as trial endpoints using mixed models.
    Korn EL; Albert PS; McShane LM
    Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of surrogate markers in multiple randomized clinical trials with repeated measurements: canonical correlation approach.
    Alonso A; Geys H; Molenberghs G; Kenward MG; Vangeneugden T
    Biometrics; 2004 Dec; 60(4):845-53. PubMed ID: 15606404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Surrogate and true endpoints in cancer clinical trials].
    Nakajima T; Ohta K; Ohyama S; Yamaguchi T
    Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical issues arising in an exploratory analysis evaluating progression-free survival as a surrogate endpoint for overall survival in advanced colorectal cancer.
    Hughes MD
    Stat Methods Med Res; 2008 Oct; 17(5):487-95. PubMed ID: 18285440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A unifying approach for surrogate marker validation based on Prentice's criteria.
    Alonso A; Molenberghs G; Geys H; Buyse M; Vangeneugden T
    Stat Med; 2006 Jan; 25(2):205-21. PubMed ID: 16220497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
    Piedbois P; Miller Croswell J
    Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new and rapid scoring system to assess the scientific evidence from clinical trials.
    Silber S
    J Interv Cardiol; 2006 Dec; 19(6):485-92. PubMed ID: 17107362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative methods to evaluate trial level surrogacy.
    Abrahantes JC; Shkedy Z; Molenberghs G
    Clin Trials; 2008; 5(3):194-208. PubMed ID: 18559408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.